Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis

被引:20
|
作者
Qiu, Shiyuan [1 ,3 ]
Zhang, Hengci [2 ]
Yu, Sijie [3 ]
Yang, Qin [3 ]
Zhang, Gaofu [3 ]
Yang, Haiping [3 ]
Li, Qiu [3 ]
Wang, Mo [3 ]
机构
[1] Chongqing You You Baobei Womens & Childrens Hosp, Pediat Internal Med Dept, Chongqing, Peoples R China
[2] Guizhou Med Univ, Guiyang, Peoples R China
[3] Chongqing Med Univ, Dept Nephrol,Minist Educ,Key Lab Child Dev & Diso, Natl Clin Res Ctr Child Hlth & Disorders,China In, Childrens Hosp,Chongqing Key Lab Pediat, Chongqing, Peoples R China
关键词
Systemic lupus erythematosus; Lupus nephritis; Children; Prognosis; DISEASE-ACTIVITY STATE; ERYTHEMATOSUS; SLE; CLASSIFICATION; VALIDATION; REMISSION; EFFICACY; CRITERIA; CHILDREN; SAFETY;
D O I
10.1007/s00467-021-05164-y
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Pediatric lupus nephritis (pLN) is one of the most refractory secondary kidney diseases in childhood. The treat-to-target (T2T) strategy has become the standard treatment for systemic lupus erythematosus (SLE). This study reviewed clinical features, overall remission status, and factors affecting prognosis, to guide pLN management according to T2T strategy. Methods This single-center retrospective study studied 220 children diagnosed with LN from January 2012 to December 2018, with > 6-month follow-up data on 173 and complete data on 137 patients. Primary outcome was treatment failure (deterioration or no response) at the latest follow-up. Results The most common pLN manifestation was proteinuria (81.36%). Females presented more often with rash (P<0.001) and alopecia (P=0.026) than males. Class IV LN (33.33%) was the most common grade on kidney biopsy. Median follow-up was 27.20 months (IQR, 15.78-44.45 months). One-, 3-, and 5-year cumulative overall survival rates were 93.5%, 87.8%, and 86.5%, respectively. The 5-year cumulative kidney survival rate was 97.1%. Regarding initial therapy, efficacy of corticosteroids combined with immunosuppressive agents was significantly better than corticosteroids alone (P=0.010). Factors with P<0.05 in univariate analysis, including hypoalbuminemia, higher SCr at diagnosis, lower eGFR at diagnosis, anti-dsDNA positivity, heavy proteinuria, hypertension, nervous-system involvement, treatment non-compliance, and SLEDAI-2K score, were used for logistic regression analysis. Logistic regression analysis showed hypertension (OR=0.845, P=0.011), nervous-system involvement (OR=4.240, P=0.005), treatment non-compliance (OR=6.433, P=0.001), and lower estimated glomerular filtration rate at diagnosis (OR=1.020, P=0.021) affected prognosis. At end of follow-up, 34.31% achieved varying levels of remission, and 8.76% were in low disease activity state (LDAS). Conclusions pLN usually presented with proteinuria, and class IV LN was the dominant pathology. Hypertension, nervous-system involvement, treatment non-compliance, and lower eGFR at diagnosis were independent risk factors for poor prognosis of kidney outcomes. Compared with renal remission rate and cumulative overall survival rate, the proportion of targets achieved was not ideal, suggesting T2T strategy should be used to guide pLN management.
引用
收藏
页码:367 / 376
页数:10
相关论文
共 50 条
  • [1] Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis
    Shiyuan Qiu
    Hengci Zhang
    Sijie Yu
    Qin Yang
    Gaofu Zhang
    Haiping Yang
    Qiu Li
    Mo Wang
    Pediatric Nephrology, 2022, 37 : 367 - 376
  • [2] Is Treat-to-target in Lupus Nephritis Realistic in Clinical Practice?
    Mok, Chi Chiu
    CURRENT RHEUMATOLOGY REVIEWS, 2019, 15 (01) : 2 - 6
  • [3] Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?
    Parodis, Ioannis
    Tamirou, Farah
    Houssiau, Frederic A.
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2022, 70 (01)
  • [4] Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?
    Ioannis Parodis
    Farah Tamirou
    Frédéric A. Houssiau
    Archivum Immunologiae et Therapiae Experimentalis, 2022, 70
  • [5] Working Towards a Treat-to-Target Protocol in Juvenile Proliferative Lupus Nephritis - A Survey of Pediatric Rheumatologists and Nephrologists in Germany and Austria
    Vollbach, Kristina
    Schuetz, Catharina
    Hedrich, Christian M.
    Speth, Fabian
    Moenkemoeller, Kirsten
    Brunner, Juergen
    Neudorf, Ulrich
    Rietschel, Christoph
    Hospach, Anton
    Kallinich, Tilmann
    Hinze, Claas
    Wagner, Norbert
    Toenshoff, Burkhard
    Weber, Lutz T.
    Latta, Kay
    Thumfart, Julia
    Bald, Martin
    Wiemann, Dagobert
    Zappel, Hildegard
    Tenbrock, Klaus
    Haffner, Dieter
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [6] Treat-to-Target in Pediatric Rheumatic Diseases
    Rosina, Silvia
    Rebollo-Gimenez, Ana Isabel
    Consolaro, Alessandro
    Ravelli, Angelo
    CURRENT RHEUMATOLOGY REPORTS, 2023, 25 (11) : 226 - 235
  • [7] Treat-to-Target in Pediatric Rheumatic Diseases
    Silvia Rosina
    Ana Isabel Rebollo-Giménez
    Alessandro Consolaro
    Angelo Ravelli
    Current Rheumatology Reports, 2023, 25 : 226 - 235
  • [8] Systemic lupus erythematosus: An update on treat-to-target
    Roberts, Amy Lynn
    Rizzolo, Denise
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2015, 28 (09): : 22 - 28
  • [9] Treat-to-target in systemic lupus erythematosus: Where are we?
    Rios-Garces, Roberto
    Espinosa, Gerard
    van Vollenhoven, Ronald
    Cervera, Ricard
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 74 : 29 - 34
  • [10] Treat-to-target in systemic lupus erythematosus: are we there yet?
    Mok, Chi Chiu
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (05) : 675 - 680